Inhibikase Therapeutics Statistics
Total Valuation
IKT has a market cap or net worth of $115.02 million. The enterprise value is $37.70 million.
Important Dates
The last earnings date was Friday, November 14, 2025, after market close.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
IKT has 75.18 million shares outstanding. The number of shares has increased by 1,080.00% in one year.
| Current Share Class | 74.52M |
| Shares Outstanding | 75.18M |
| Shares Change (YoY) | +1,080.00% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 6.45% |
| Owned by Institutions (%) | 26.44% |
| Float | 24.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.57 |
| P/TBV Ratio | 1.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.73
| Current Ratio | 11.73 |
| Quick Ratio | 11.55 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -131.71% and return on invested capital (ROIC) is -88.05%.
| Return on Equity (ROE) | -131.71% |
| Return on Assets (ROA) | -76.11% |
| Return on Invested Capital (ROIC) | -88.05% |
| Return on Capital Employed (ROCE) | -70.14% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.98M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.78% in the last 52 weeks. The beta is 0.89, so IKT's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | -36.78% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | 1.91 |
| Relative Strength Index (RSI) | 46.84 |
| Average Volume (20 Days) | 102,353 |
Short Selling Information
The latest short interest is 3.03 million, so 4.03% of the outstanding shares have been sold short.
| Short Interest | 3.03M |
| Short Previous Month | 3.20M |
| Short % of Shares Out | 4.03% |
| Short % of Float | 12.13% |
| Short Ratio (days to cover) | 32.16 |
Income Statement
| Revenue | n/a |
| Gross Profit | -17.21M |
| Operating Income | -51.13M |
| Pretax Income | -47.66M |
| Net Income | -47.66M |
| EBITDA | -51.06M |
| EBIT | -51.13M |
| Earnings Per Share (EPS) | -$0.56 |
Full Income StatementBalance Sheet
The company has $77.32 million in cash and n/a in debt, giving a net cash position of $77.32 million or $1.03 per share.
| Cash & Cash Equivalents | 77.32M |
| Total Debt | n/a |
| Net Cash | 77.32M |
| Net Cash Per Share | $1.03 |
| Equity (Book Value) | 72.90M |
| Book Value Per Share | 0.97 |
| Working Capital | 71.84M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$25.62 million and capital expenditures -$13,399, giving a free cash flow of -$25.63 million.
| Operating Cash Flow | -25.62M |
| Capital Expenditures | -13,399 |
| Free Cash Flow | -25.63M |
| FCF Per Share | -$0.34 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
